Intralesional immunotherapy employing skin test (recall) antigens derived from mumps, Candida, and Trichophyton is an effective and safe treatment for verruca vulgaris and verruca plana.1,2 In adults, we have shown individual treated wart response rates of 60% to 74% (saline control, 22%) and complete clearing of uninjected anatomically distinct and distant warts in 49% to 71% (saline control, 16%). In children with treatment-resistant warts (2 modalities), complete response rates were 47% and 34%, respectively.3
King M, Johnson SM, Horn TD. Intralesional Immunotherapy for Genital Warts. Arch Dermatol. 2005;141(12):1606–1607. doi:10.1001/archderm.141.12.1606
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.